(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 August 2021 (19.08.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/160763 A1

(51) International Patent Classification:
A61K 31/498 (2006.01) *A61K 39/395* (2006.01)
A61K 31/555 (2006.01) *A61K 45/06* (2006.01)
A61K 33/243 (2019.01) *A61P 35/04* (2006.01)

(21) International Application Number:
PCT/EP2021/053384

(22) International Filing Date:
11 February 2021 (11.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/975,526	12 February 2020 (12.02.2020)	US
63/025,817	15 May 2020 (15.05.2020)	US
63/055,187	22 July 2020 (22.07.2020)	US
63/078,205	14 September 2020 (14.09.2020)	US
63/078,736	15 September 2020 (15.09.2020)	US
63/083,316	25 September 2020 (25.09.2020)	US

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventor: **MONGA, Manish**; JANSSEN RESEARCH & DEVELOPMENT, LLC 920 US Route 202 P.O. Box 300, Raritan, New Jersey 08869 (US).

(74) Agent: **VERVOORT, Liesbeth**; Turnhoutseweg 30, 2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: FGFR TYROSINE KINASE INHIBITORS AND ANTI-PD1 AGENTS FOR THE TREATMENT OF UROTHELIAL CARCINOMA

(57) Abstract: Disclosed herein are methods of treating urothelial carcinoma. In particular, the disclosed methods include combination therapies for the treatment of urothelial carcinoma comprising administering a fibroblast growth factor receptor (FGFR) inhibitor and an anti- PD1 antibody or antigen binding fragment thereof.

WO 2021/160763 A1